Think Bioscience
PrivateLast Round
Series A
Jan 20, 2026
Total Funding Raised
$81.15M
Momentum Score
50 /100
Company Overview
Think Bioscience is a synthetic biology company that develops small-molecule therapeutics designed to target proteins that are historically difficult to drug. The company's proprietary platform uses living microbial systems to identify, build, and evolve novel small molecules. This approach combines applied microbiology, enzymology, and data science to discover new medicines for challenging targets. A spin-out from the University of Colorado Boulder, Think Bioscience is focused on several therapeutic areas, including oncology, autoimmune, and metabolic diseases. The company has received venture backing to expand its drug discovery platform and advance its internal development programs.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Think Bioscience Comps
Public and private peers based on sector, stage, and business model.
Think Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 20, 2026 | ||||
| Seed | May 7, 2024 | ||||
| Grant | Nov 25, 2022 | ||||
| Seed | Aug 18, 2022 | ||||
| Pre Seed | Sep 20, 2021 | ||||
Grant | Nov 19, 2020 |
Key People
Founding team and executive leadership
Think Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| National Institute of Allergy and Infectious Diseases | Grant |
| Xora Innovation | Pre Seed, Seed |
| Regeneron Ventures | Series A |
| Wireframe Ventures | Pre Seed, Seed, Grant |
| Innovation Endeavors | Series A, Seed |
| CE-Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 20, 2026
$55M round completed.
Think Bioscience Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Think Bioscience's valuation, stock price, and market status.
